... occurs by a change in the normal balance between protein
synthesis and protein
degradation. During atrophy, there is a down-regulation of protein
synthesis pathways, and an activation ...
...  
The proteopathies are also called protein
conformational diseases ,  because a change in the 3-dimensional folding (conformation) of a protein
increases the tendency of the protein
to misfold and polymerize into aggregates that ...
... by the T cell receptor , which is a surface protein
able to recognise short protein
sequences ( peptides ) that are presented on MHC ... is capable to binding a pre-T cell receptor alpha protein
and assembling on the surface with the signalling ...
Atransferrinemia is a genetic disorder in which there is absence of transferrin , a plasma protein
that transports iron through the blood .
Atransferrinemia is characterized by anemia and hemosiderosis in the heart and liver . The iron ...
Cryostasis (clathrate hydrates)
... Am. J. Physiol. 1984;247:125–147 . Retrieved on 2007 - 01-03 .
^ Graham L.A., Liou Y.-C., Walker V. K., Davies P. L. Hyperactive antifreeze protein
from beetles. Nature 1997;388:727–728 . Retrieved on 2007 - 01-03 .
^ Fletcher G.L., Hew C.L., Davies P.L. Antifreeze Proteins of Teleost ...
Neurobiological Brain Disorder
... and Psychiatric Manifestations:
Identifying hypothyroidism’s psychiatric presentations
Lingering Psychiatric Symptoms From Hyperthyroidism
Biomarkers for Schizophrenia Studied in Cerebrospinal Fluid ...
... Keck, P.E, McElroy, S L, Alexander, L., Shaw, S.H., & Kelsoe, J. (2003) Evidence that a single nucleotide polymorphism in the promoter of the G protein
receptor kinase 3 gene is associated with bipolar disorder. Molecular Psychiatry, 8, 546−557.
Baughman, F.A., & Hovey, J. (2006) The ADHD ...
... theranostic test. Herceptin treats a category of breast cancer in woman and the test helps identify those patients whose cancer cells express the protein
HER2 making them eligible. Herceptin sales have grown from $30.5 million in 1998, its year of introduction, to $764 million in 2005. Gleevec treats ...